Niki BioSolutions, Inc. · NASDAQ:NIKI
Niki BioSolutions — H.C. Wainwright Global Investment Conference, September 2026
21 slides from Niki BioSolutions's conference presentation, Sep 14, 2026
Slide 1: H.C. Wainwright Global Investment Conference, September 2026
Alidad Mireskandari, Ph.D. President & COO H.C. Wainwright Global Investment Conference, September 2026 NASDAQ: NIKI
Slide 2: Forward-Looking Statements Legal Disclaimer
Forward-Looking Statements Legal Disclaimer This presentation contains summary information about Niki BioSolutions, Aptorum Group Limited and DiamiR Biosciences Corp. (collectively, the "Companies") as of the date hereof. The information in this presentation is of general background and contains an
Slide 3: Niki BioSolutions | Aptorum Group merger with DiamiR Biosciences
Niki BioSolutions | Aptorum Group merger with DiamiR Biosciences All-stock merger completed July 20, 2026 · DiamiR ~70% / Aptorum ~30% of combined company Jul 16, 2025 Definitive merger agreement Oct 10, 2025 Board and management expansion Jun 9, 2026 Shareholders approved merger Jul 20, 2026 Merger
Slide 4: Niki BioSolutions | DiamiR subsidiary profile
Niki BioSolutions | DiamiR subsidiary profile Focus: Developing Molecular Diagnostics and Pharma Services Testing Solutions Specialization: Non-invasive blood-based diagnostic solutions for Alzheimer's disease and brain health Infrastructure: CLIA-licensed, CAP-accredited, NY State-licensed clinical
Slide 5: Our mission | Helping defuse the Alzheimer's disease time bomb
Our mission | Helping defuse the Alzheimer's disease time bomb An expanding patient population and escalating care costs reinforce the need for scalable testing solutions Opportunities for Niki BioSolutions Scalable blood test to identify Alzheimer's disease for early intervention Testing solutions
Slide 6: Dual growth engines | Pharma Services and Clinical Services
Dual growth engines | Pharma Services and Clinical Services Alzheimer's disease testing market is large, underserved, and fragmented, dominated by imaging and cognitive testing options Clinical Services: Develop clinical solutions for early testing options that Are non-invasive and blood-based Diffe
Slide 7: Product pipeline | Diagnostic and therapeutic
Product pipeline | Diagnostic and therapeutic Our microRNA platform is expanding from brain health into rare disease and neuro-oncology Discovery Development Analytical validation Clinical validation Launch APOE genotyping NY State-approved · 1st Pharma customer signed CogniMIR® (Alzheimer's risk) A
Slide 8: Research partners, collaborators and scientific advisors
Research partners, collaborators and scientific advisors Henry (Harv) Rinder, MD Vice Chair of Diagnostics, Yale University. Head of laboratory medicine and clinical hematology leader; former president of the American Society for Clinical Pathology. Robert Rissman, Ph.D. USC neuroscience professor a
Slide 9: Pharma Services Opportunity, Positioning, and Solutions
Pharma Services Opportunity, Positioning, and Solutions Near-term revenue + validation engine
Slide 10: Drug trials in AD | Two decades of failure, 2002–2021
Drug trials in AD | Two decades of failure, 2002–2021 18 years between new drug approvals 0.4% Overall approval rate 2002–2012: 413 trials, 244 agents, 1 approval (memantine) Cummings et al. 2014 98 unique compounds failed Unique compounds failed in Phase 2/3, 2004–2021 (40 of them in Phase 3; 64% d
Slide 11: Alzheimer's Disease Biology | Brain changes occur decades before symptoms appear
Alzheimer's Disease Biology | Brain changes occur decades before symptoms appear AD Disease Biology 10–25 years Average lead time stated for synaptic dysfunction before loss of cognition and clinical function Biomarker changes occur before symptoms Biomarkers can be measured in the blood/plasma Offe
Slide 12: Blood-based biomarkers | From the 2018 shift to pharma value
Blood-based biomarkers | From the 2018 shift to pharma value NIA-AA's 2018 pathology-based definition of Alzheimer's put blood assays at the center of trial selection. The biomarker toolkit CORE DIAGNOSTIC Establish AD pathology Plasma p-tau217 — FDA 510(k) cleared Plasma Aβ42/40 ratio — FDA 510(k)
Slide 13: Biomarker adoption is now the baseline expectation, not a differentiator
Biomarker adoption is now the baseline expectation, not a differentiator | Regulators, guidelines & industry are aligned Regulatory precedent with recent approvals • Accelerated approvals of aducanumab (June 2021) and lecanemab (Jan 2023) rested on amyloid reduction as a surrogate • Traditional appr
Slide 14: Validated programs | Creating a repeatable path to contract revenue
Validated programs | Creating a repeatable path to contract revenue Pipeline programs can generate near-term pharma-services revenue while clinical-service commercialization matures. COMMERCIALIZATION PATH 1 Assay readiness Classifier development; marker, vendor and platform selection 2 Analytical v
Slide 15: Pharma Services | Our menu of services
Pharma Services | Our menu of services AVAILABLE NOW APOE genotyping • NY State-approved APOE test in routine operation • Supports ARIA-risk stratification, eligibility and randomization by ε4 dose • First pharma customer contract signed; revenue- generating from 3Q 2026 AVAILABLE NOW Custom ELISA a
Slide 16: Clinical Solutions: Testing solutions for precision care
Clinical Solutions Testing solutions for precision care Long-term revenue growth opportunity
Slide 17: Patient testing | Biomarker testing reduces diagnostic uncertainty
Patient testing | Biomarker testing reduces diagnostic uncertainty Earlier, biologically confirmed diagnosis removes the guesswork WHAT BIOMARKERS ENABLE FOR PATIENTS Earlier and more accurate diagnosis Treatment eligibility and safety Fast track specialist access FROM VARIABILITY TO STANDARDIZATION
Slide 18: microRNA + protein biomarker testing | Complementary approaches
microRNA + protein biomarker testing | Complementary approaches Protein biomarkers confirm established amyloid and tau pathology; microRNAs capture upstream neuroinflammatory and synaptic changes, allowing earlier detection plus pathology-specific confirmation. Circulating microRNAs • Small non-codi
Slide 19: CogniMIR® | A proprietary, novel, multiplatform, risk-assessment tool for AD
CogniMIR® | A proprietary, novel, multiplatform, risk-assessment tool for AD Plasma Shipped to our CLIA Lab microRNA Risk Profiling Other Risk Factors Analyzed -Protein Biomarkers -Age -APOE -Gender ML/Algorithm/AI Risk Assessment Report Generated * Diagnostics 2023, 13, 2170. https://doi.org/10.339
Slide 20: Summary | Blood-based diagnostics platform with two growth paths
Summary | Blood-based diagnostics platform with two growth paths Growth fueled by unmet need, validated science, and a scalable delivery model KEY GROW TH DRIVERS Adoption of biomarkers FDA-accepted surrogate endpoints Regulatory support Expedited approvals and reimbursement coverage Demographic tre
Slide 21: Thank You – Q&A
Thank You – Q&A Investor relations contact information: Lytham Partners [email protected]
Niki BioSolutions — H.C. Wainwright Global Investment Conference, September 2026 on 6ix